

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



国药集团
SINOPHARM

國藥控股股份有限公司 SINOPHARM GROUP CO. LTD.*

(A joint stock limited company incorporated in the People's Republic of China with limited liability and carrying on business in Hong Kong as 國控股份有限公司)
(Stock Code: 01099)

ANNOUNCEMENT PRINCIPAL FINANCIAL DATA OF SINOPHARM (CNCM LTD) FOR THE NINE MONTHS ENDED 30 SEPTEMBER 2019

This announcement is made pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong).

Reference is made to the overseas regulatory announcement of Sinopharm Group Co. Ltd. (the “**Company**”) dated 23 October 2019 (the “**Announcement**”) in relation to the third quarterly report for the nine months ended 30 September 2019 of China National Medicines Corporation Ltd. (“**SINOPHARM (CNCM LTD)**”), a subsidiary of the Company and whose A shares are listed on the Shanghai Stock Exchange (stock code: 600511).

The board of directors of the Company would like to draw the attention of its shareholders and the public investors to the following principal unaudited financial data of SINOPHARM (CNCM LTD) for the nine months ended 30 September 2019 as set out in the Announcement.

PRINCIPAL FINANCIAL DATA OF SINOPHARM (CNCM LTD)

Unit: Yuan
Currency: RMB

	As at the end of this reporting period	As at the end of last year	Increase/decrease at the end of this reporting period as compared with the end of last year (%)
Total assets	24,264,517,325.33	21,509,768,350.39	12.81
Net assets attributable to shareholders of listed company	10,000,623,286.48	9,232,394,076.27	8.32
	From the beginning of the year to the end of the reporting period (January - September)	From the beginning of last year to the end of the same period of the last year (January - September)	Increase/decrease as compared with the same period of last year (%)
Net cash flow arising from operating activities	1,082,316,553.09	924,639,404.21	17.05
	From the beginning of the year to the end of the reporting period (January - September)	From the beginning of last year to the end of the same period of the last year (January - September)	Increase/decrease as compared with the same period of last year (%)
Operating income	32,709,864,477.48	28,777,116,460.43	13.67
Net profit attributable to shareholders of the listed company	1,071,317,614.60	950,487,969.99	12.71
Net profit attributable to shareholders of the listed company net of non-recurring gain or loss	1,037,768,857.22	940,111,713.17	10.39
Weighted average return on net assets (%)	11.16%	11.28%	decreased by 0.12 percentage point
Basic earnings per share (RMB/Share)	1.4015	1.2393	13.09
Diluted earnings per share (RMB/Share)	1.4015	1.2393	13.09

By order of the Board
Sinopharm Group Co. Ltd.
Li Zhiming
Chairman

Shanghai, the PRC
23 October 2019

As at the date of this announcement, the executive directors of the Company are Mr. Li Zhiming, Mr. Yu Qingming and Mr. Liu Yong; the non-executive directors of the Company are Mr. Chen Qiyu, Mr. Ma Ping, Mr. Hu Jianwei, Mr. Deng Jindong, Mr. Wen Deyong, Ms. Guan Xiaohui and Ms. Dai Kun; and the independent non-executive directors of the Company are Mr. Yu Tze Shan Hailson, Mr. Tan Wee Seng, Mr. Liu Zhengdong, Mr. Zhuo Fumin and Mr. Chen Fangruo.

** The Company is registered as a non-Hong Kong company under the Hong Kong Companies Ordinance under its Chinese name and the English name "Sinopharm Group Co. Ltd.".*